Variasi Manifestasi Klinis Adverse Cutaneous Drug Reaction (ACDR) pada Pasien di RS Atma Jaya Tahun 2020-2024

Patterns of Clinical Manifestation in Adverse Cutaneous Drug Reactions (ACDR) in Patients at Atma Jaya Hospital from 2020 to 2024

Authors

  • dr. Regina, Sp.DVE Universitas Katolik Indonesia Atma Jaya Author https://orcid.org/0000-0002-0558-8929
  • Dr. dr. Lorettha Wijaya, Sp.DVE Universitas Katolik Indonesia Atma Jaya Author
  • dr. Christina Jeanny Soekiono Rumah Sakit Atma Jaya Author

DOI:

https://doi.org/10.30872/jsk.v6i2.749

Keywords:

adverse cutaneous drug reaction, fixed drug reaction, antibiotics, acdr

Abstract

Prevalensi adverse cutaneous drug reaction (ACDR) terus meningkat seiring dengan tingginya penggunaan obat di populasi global. Di Indonesia, data mengenai variasi manifestasi klinis ACDR masih terbatas, terutama dalam konteks pelayanan kesehatan di rumah sakit swasta. Penelitian ini bertujuan untuk melihat variasi manifestasi klinis ACDR pada pasien di RS Atma Jaya selama periode 2020-2024. Studi ini menggunakan data sekunder yang diperoleh dari rekam medis untuk mengetahui karakteristik klinis dan demografis, riwayat pengobatan dan luaran klinis pasien. Sebanyak 17 pasien dengan ACDR tercatat, dengan rerata usia 49,9 ± 20,8 tahun (rentang 18-80 tahun), dan proporsi laki-laki lebih tinggi dibandingkan perempuan. Manifestasi klinis ACDR yang paling sering ditemukan adalah fixed drug eruption (FDE) sebesar 29,4%, diikuti dengan erupsi makulopapular, eritroderma dan Stevens-Johnson Syndrome (SJS), masing-masing sebesar 17,6%. Komorbiditas yang paling banyak dijumpai adalah diabetes melitus (22,2%), hipertensi (14,8%) dan penyakit gagal ginjal (14,8%). Jenis obat yang paling banyak dikonsumsi pasien sebelum timbulnya ACDR adalah antibiotik (16,7%), antihipertensi (14,3%) dan parasetamol (11,9%). Temuan ini menegaskan pentingnya untuk mengenali variasi manifestasi klinis ACDR serta pemantauan ketat dalam penggunaan obat-obatan yang diketahui memiliki potensi tinggi dalam memicu ACDR.

References

[1] K. Sewon et al., Fitzpatrick’s Dermatology, 9th ed. McGraw Hill, 2019.

[2] D. M. A. Aboud, T. A. Nessel, and W. Hafsi, ‘Cutaneous Adverse Drug Reaction’, Treasure Isl. FL StatPearls Publ., Apr. 2023.

[3] W. J. Pichler and O. Hausmann, ‘Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms’, Int. Arch. Allergy Immunol., vol. 171, no. 3–4, pp. 166–179, 2016, doi: 10.1159/000453265.

[4] L. Maharani and A. Yugatama, ‘Prevalence of adverse drug reaction in Indonesia: A systematic review’, J. Appl. Pharm. Sci., 2023, doi: 10.7324/JAPS.2023.91550.

[5] T. Patel, S. Thakkar, and D. Sharma, ‘Cutaneous adverse drug reactions in Indian population: A systematic review’, Indian Dermatol. Online J., vol. 5, no. 6, p. 76, 2014, doi: 10.4103/2229-5178.146165.

[6] D. A. M. Oktarina, M. Sophiati, E. M. R. Moha, F. Waskito, and H. Soebono, ‘A Five-Year Review of Adverse Cutaneous Drug Reaction in a Tertiary Care Hospital in Yogyakarta, Indonesia’, Berk. Ilmu Kesehat. Kulit Dan Kelamin, vol. 33, no. 3, p. 150, Nov. 2021, doi: 10.20473/bikk.V33.3.2021.150-155.

[7] M. B. Zazzara, K. Palmer, D. L. Vetrano, A. Carfì, and G. Onder, ‘Adverse drug reactions in older adults: a narrative review of the literature’, Eur. Geriatr. Med., vol. 12, no. 3, pp. 463–473, Jun. 2021, doi: 10.1007/s41999-021-00481-9.

[8] S. Rana, K. Gupta, N. Agarwal, and A. N. M. Ahamed, ‘A Study of Cutaneous Adverse Drug Reactions and their Association with Autoimmune Diseases at a Tertiary Centre in South-West Rajasthan, India’, Indian J. Dermatol., vol. 66, no. 4, p. 445, Jul. 2021, doi: 10.4103/ijd.IJD_261_17.

[9] R. Alfadli, S. Khairunisa, B. Alprida, B. J. Rosaline, D. I. Zahra, and N. D. Darsono, ‘Unveiling the clinical profiles and triggers of adverse cutaneous drug reactions at Jagakarsa general hospital’, Int. J. Res. Dermatol., vol. 11, no. 2, pp. 126–132, Feb. 2025, doi: 10.18203/issn.2455-4529.IntJResDermatol20250431.

[10] M. Z. Banday, A. S. Sameer, and S. Nissar, ‘Pathophysiology of diabetes: An overview’, Avicenna J. Med., vol. 10, no. 04, pp. 174–188, Oct. 2020, doi: 10.4103/ajm.ajm_53_20.

[11] J. Kowalska and D. Wrześniok, ‘Skin-Related Adverse Reactions Induced by Oral Antidiabetic Drugs—A Review of Literature and Case Reports’, Pharmaceuticals, vol. 17, no. 7, p. 847, Jun. 2024, doi: 10.3390/ph17070847.

[12] S. M. Laville et al., ‘Adverse Drug Reactions in Patients with CKD’, Clin. J. Am. Soc. Nephrol., vol. 15, no. 8, pp. 1090–1102, Aug. 2020, doi: 10.2215/CJN.01030120.

[13] K. M. Smaha, N. N. Talebi, J. L. Waller, S. L. Baer, and W. B. Bollag, ‘Impact of non-genetic factors on severe cutaneous adverse reactions and associated mortality in ESRD patients: Advancing clinical guidance’, Am. J. Med. Sci., vol. 369, no. 5, pp. 613–619, May 2025, doi: 10.1016/j.amjms.2025.02.007.

[14] C. A. Chindhalore, A. V. Gupta, G. N. Dakhale, and A. Srivastava, ‘Analysis of Cutaneous Adverse Drug Reactions Reported at an ADR Monitoring Center of a Tertiary Care Teaching Institute in Central India’, Cureus, Feb. 2024, doi: 10.7759/cureus.53706.

[15] R. Vora, T. Patel, J. Tandel, J. Patel, and R. Polra, ‘Adverse cutaneous drug reactions at a rural-based tertiary health-care center in Gujarat: An eleven year study’, Indian Dermatol. Online J., vol. 14, no. 1, p. 50, 2023, doi: 10.4103/idoj.idoj_85_22.

[16] E. Lee et al., ‘Oral Antibiotics and the Risk of Serious Cutaneous Adverse Drug Reactions’, J. Allergy Clin. Immunol., vol. 153, no. 2, p. AB164, Feb. 2024, doi: 10.1016/j.jaci.2023.11.536.

[17] E. M. Sokolewicz, M. Rogowska, M. Lewandowski, M. Puchowska, D. Piechota, and W. Barańska-Rybak, ‘Antibiotic-Related Adverse Drug Reactions in Patients Treated on the Dermatology Ward of Medical University of Gdańsk’, Antibiotics, vol. 10, no. 10, p. 1144, Sep. 2021, doi: 10.3390/antibiotics10101144.

[18] A. Nangia, R. Mukhija, M. Misra, L. Mohan, K. Singh, and J. Upadhayai, ‘Cutaneous reactions due to antihypertensive drugs’, Indian J. Dermatol., vol. 51, no. 3, p. 189, 2006, doi: 10.4103/0019-5154.27982.

[19] D. Baccino et al., ‘Cutaneous effects of antihypertensive drugs’, G. Ital. Dermatol. Venereol., vol. 155, no. 2, May 2020, doi: 10.23736/S0392-0488.19.06360-0.

[20] M. Bose, D. Misra, S. Parida, S. Das, S. Mishra, and S. S. Mishra, ‘Adverse cutaneous drug reactions reporting in a tertiary care teaching hospital in Eastern India: a retrospective study’, Int. J. Basic Clin. Pharmacol., vol. 9, no. 9, p. 1381, Aug. 2020, doi: 10.18203/2319-2003.ijbcp20203623.

[21] A. Modi, M. Desai, S. Shah, and B. Shah, ‘Analysis of cutaneous adverse drug reactions reported at the regional ADR monitoring center’, Indian J. Dermatol., vol. 64, no. 3, p. 250, 2019, doi: 10.4103/ijd.IJD_682_16.

[22] D. Cebeci̇, Ş. Yaşar, S. Ayteki̇N, F. Göktay, and P. Güneş, ‘An epidemiological and clinical analysis of cutaneous drug eruption: A cohort of 164 patients’, J. Surg. Med., vol. 4, no. 12, pp. 1147–1151, Dec. 2020, doi: 10.28982/josam.751196.

[23] D. Saha, S. A. Begum, S. Sarkar, N. Gupta, S. Sen, and S. K. Tripathi, ‘NSAIDS induced cutaneous adverse drug reaction – a case series’, Int. J. Health Clin. Res., vol. 3, no. 5, pp. 6–10, Sep. 2020, Accessed: Jun. 02, 2025. [Online]. Available: https://ijhcr.com/index.php/ijhcr/article/view/140

[24] F. Angeletti, F. Meier, N. Zöller, M. Meissner, R. Kaufmann, and E. M. Valesky, ‘Hypersensitivity reactions to non‐steroidal anti‐inflammatory drugs (NSAIDs) – a retrospective study’, JDDG J. Dtsch. Dermatol. Ges., vol. 18, no. 12, pp. 1405–1414, Dec. 2020, doi: 10.1111/ddg.14292.

[25] R. Vora, S. Rochit R, P. Trusha M, and M. Khushboo H, ‘A Study of Adverse Cutaneous Drug Reactions Due to Nsaids at a Rural Based Tertiary Care Centre, Gujarat’, Int. J. Pharmacovigil., vol. 3, no. 1, pp. 1–4, May 2018, doi: 10.15226/2476-2431/3/1/00123.

[26] C. Sonsupap, P. Pokhakul, T. Kariya, Y. Suzuki, N. Hamajima, and E. Yamamoto, ‘Characteristics of adverse drug reactions due to nonsteroidal anti-inflammatory drugs: a cross-sectional study’, Nov. 2023, Nagoya University Graduate School of Medicine, School of Medicine: 4. doi: 10.18999/nagjms.85.4.668.

Downloads

Published

2025-11-10

Issue

Vol. 6 No. 2 (2025)

Section

Articles

License

Copyright (c) 2025 Jurnal Sains dan Kesehatan

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

[1]
Regina, L. Wijaya, and C. J. . Soekiono, “Variasi Manifestasi Klinis Adverse Cutaneous Drug Reaction (ACDR) pada Pasien di RS Atma Jaya Tahun 2020-2024: Patterns of Clinical Manifestation in Adverse Cutaneous Drug Reactions (ACDR) in Patients at Atma Jaya Hospital from 2020 to 2024”, J. Sains. Kes, vol. 6, no. 2, pp. 1–7, Nov. 2025, doi: 10.30872/jsk.v6i2.749.

Most read articles by the same author(s)

Similar Articles

21-29 of 29

You may also start an advanced similarity search for this article.